BioSyent Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- René C. Goehrum
- Full Time Employees
- 60
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2476 Argentia Road Mississauga ON Canada L5N 6M1
- IPO Date
- Feb 22, 2012
- Website
- biosyent.com
- Similar Companies
- Business
- BioSyent Inc., a specialized pharmaceutical enterprise, focuses on the procurement, licensing, and advancement of a diverse array of medicinal and health-related offerings across Canada and select global territories. Its portfolio features FeraMAX Pd Therapeutic 150, an oral treatment for iron deficiency anemia, alongside FeraMAX Pd Powder 15, a water-soluble variant, and FeraMAX Pd Maintenance 45, a chewable option with added vitamins for prevention. FeraMAX holds a leading position as a pharmacist and physician recommended iron supplement in Canada. The company also provides solutions for women's well-being, including RepaGyn, a hormone-free vaginal suppository designed to aid in the restoration of vaginal tissue and alleviate dryness. Additionally, Tibella offers a hormone replacement therapy for addressing menopausal vasomotor symptoms. More recently, Inofolic was introduced to support women dealing with symptoms of polycystic ovarian syndrome. For urological and procedural needs, Cathejell provides a sterile anesthetic lubricating gel for use during examinations, intubations, and for comfort in conditions like cystitis. Combogesic, the pioneering single-tablet combination of acetaminophen and ibuprofen in Canada, is available for the temporary management of mild to moderate acute pain and fever. Proktis-M, a hyaluronic acid-based rectal suppository, supports the healing process for the anus and rectum, particularly for hemorrhoids and fissures. Gelclair is also offered, a gel designed to relieve the discomfort of oral mucositis. Beyond pharmaceuticals, the firm maintains a legacy segment with Protect-It, a non-chemical grain insecticide for safeguarding stored crops. Distribution of its products occurs through pharmaceutical wholesalers and prominent retail pharmacy chains. Recent strategic moves include the September 2024 acquisition of global rights for Tibelia® assets, expanding its hormone replacement therapy reach, and the June 2024 in-licensing of a new endocrinology product for the Canadian market. The company continues to show robust financial performance. Originally operating as Hedley Technologies Inc., the company adopted the BioSyent Inc. name in June 2006 to reflect its specialized pharmaceutical focus. It is headquartered in Mississauga, Canada.
BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)
BioSyent Declares Second Quarter 2026 Dividend
BioSyent Releases Financial Results for First Quarter 2026
BioSyent Schedules First Quarter 2026 Earnings Release for May 14, 2026
BioSyent to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
BioSyent Announces Grant of Restricted Share Units
BioSyent Inc. (RX:CA) Q4 2025 Earnings Call Prepared Remarks Transcript
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026
BioSyent Announces Closing of the Acquisition of Oral Science Inc.
BioSyent to Acquire Oral Science Inc.
BioSyent Declares First Quarter 2026 Dividend
BioSyent Inc. (RX:CA) Q3 2025 Earnings Call Prepared Remarks Transcript
BioSyent Releases Financial Results for Q3 and YTD 2025
BioSyent Declares Fourth Quarter 2025 Dividend
BioSyent Releases Financial Results for Q2 and H1 2025
BioSyent Declares Third Quarter 2025 Dividend
BioSyent Schedules Q2 and H1 2025 Earnings Release for August 21, 2025
BioSyent Inc. (BIOYF) Q1 2025 Earnings Call Transcript
BioSyent Releases Financial Results for First Quarter 2025